Daré Bioscience, Inc. (DARE) Key Metrics
DARE valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $14.3M
- Enterprise value
- $4.3M
- P/E (TTM)
- —
- Forward P/E
- 1.3
- PEG ratio
- —
- Price / sales
- 10.4 10-yr median 9.6
- Price / book
- 29.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.01
DARE key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDARE returns How much profit the business earns on the capital it uses.
Return on assets−30.4 pts
−49.1%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin
−997.0%
2025 · hover or tap a bar for each year
20162025
Asset turnover+8,270.0%
0.04
2025 · hover or tap a bar for each year
20162025
DARE financial health Debt, liquidity and how easily interest is covered.
Debt / equity
0.93
2025 · hover or tap a bar for each year
20162025
Net debt−$7.7M
−$22.1M
2025 · hover or tap a bar for each year
20162025
Current ratio+33.8%
1.14
2025 · hover or tap a bar for each year
20162025
Interest coverage
-16.5
2025 · hover or tap a bar for each year
20162025
Debt / assets+38.7%
0.08
2025 · hover or tap a bar for each year
20162025
DARE efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−21,853 days
142 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+136 days
198 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−21,989 days
-56 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−5,819.6 pts
37.4%
2025 · hover or tap a bar for each year
20162025
DARE valuation history
Fiscal year-endToday10-year median
DARE returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DARE debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DARE cash returned to shareholders
DividendsBuybacksFree cash flow
DARE price vs earnings per share
Share price at year-endEPS (right axis)
DARE key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | — | $26.5M | $27.0M | $70.2M | $122.3M | — | — | — | — | — |
| Enterprise value | — | $12.1M | $17.9M | $36.0M | $70.9M | — | — | — | — | — |
| P/E ratio | — | — | — | 0.2 | — | — | — | — | — | — |
| Price / sales | — | — | 9.6 | 7.0 | 12.2 | — | — | — | — | — |
| Price / book | — | — | — | 6.3 | 3.2 | — | — | — | — | — |
| Price / free cash flow | — | 5.5 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | — | 4.9 | — | — | — | — | — | — | — | — |
| EV / sales | — | — | 6.4 | 3.6 | 7.1 | — | — | — | — | — |
| EV / free cash flow | — | 2.5 | — | — | — | — | — | — | — | — |
| Earnings yield | — | −15.3% | −111.8% | 579.5% | −31.6% | — | — | — | — | — |
| Free cash flow yield | — | 18.2% | −146.4% | −25.9% | −23.5% | — | — | — | — | — |
| Share price at fiscal year-end | $1.93 | $3.12 | $3.71 | $9.96 | $24.00 | $16.08 | $9.84 | $8.53 | $25.97 | $84.98 |
| Per share | ||||||||||
| Revenue per share | — | $0.00 | $0.39 | $1.42 | $1.96 | — | — | — | — | — |
| Earnings per share | — | −$0.48 | −$4.15 | $57.72 | −$7.59 | — | — | — | — | — |
| Operating cash flow per share | — | $0.63 | −$5.34 | −$2.57 | −$5.64 | — | — | — | — | — |
| Free cash flow per share | — | $0.57 | −$5.43 | −$2.58 | −$5.65 | — | — | — | — | — |
| Cash per share | — | $1.85 | $1.44 | $4.92 | $10.14 | — | — | — | — | — |
| Book value per share | — | −$0.71 | −$0.69 | $1.58 | $7.60 | — | — | — | — | — |
| Tangible book value per share | — | −$0.71 | −$0.69 | $1.58 | $7.60 | — | — | — | — | — |
| Capex per share | — | $0.07 | $0.09 | $0.01 | $0.00 | — | — | — | — | — |
| Debt per share | — | $0.15 | $0.19 | $0.07 | $0.05 | — | — | — | — | — |
| Shares outstanding | — | 8.5M | 7.3M | 7.0M | 5.1M | — | — | — | — | — |
| Change in shares outstanding | — | +16.8% | +3.2% | +38.3% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −205.8% | — | −398.0% | −167.2% | −87.1% | −127.1% |
| Return on assets (ROA) | −49.1% | −18.7% | −92.6% | 816.6% | −122.2% | −365.5% | −186.8% | −151.6% | −44.3% | −67.8% |
| Return on tangible assets | −41.3% | −18.3% | −141.7% | 928.2% | −69.3% | −362.9% | −191.6% | −213.9% | −296.1% | −104.3% |
| Free cash flow margin | −997.0% | — | — | −181.5% | −287.8% | — | — | — | — | — |
| Income quality (OCF / net income) | — | — | — | −0.04 | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $2.7M | $1.3M | $1.4M | $488,737 | $270,546 | $756,841 | $800,452 | — | $0 | $12.8M |
| Cash & short-term investments | $24.7M | $15.7M | $10.5M | $34.7M | $51.7M | $4.7M | $4.8M | $6.8M | $7.6M | $35.0M |
| Net debt | −$22.1M | −$14.4M | −$9.1M | −$34.2M | −$51.4M | −$3.9M | −$4.0M | −$6.8M | −$7.6M | −$22.1M |
| Debt / equity | 0.93 | — | — | 0.04 | 0.01 | — | 1.82 | — | 0.00 | 0.98 |
| Debt / assets | 0.08 | 0.06 | 0.07 | 0.01 | 0.00 | 0.10 | 0.11 | — | 0.00 | 0.34 |
| Current ratio | 1.14 | 0.85 | 0.86 | 1.36 | 3.44 | 0.91 | 1.15 | 6.64 | 8.64 | 2.17 |
| Quick ratio | 1.14 | 0.85 | 0.86 | 1.36 | 157.57 | 242.72 | 198.48 | 375.72 | 8.31 | 2.28 |
| Interest coverage | -16.5 | — | — | -0.1 | -104.9 | — | — | — | -34.7 | -16.6 |
| Working capital | $3.4M | −$3.2M | −$2.9M | $11.4M | $39.2M | −$676,689 | $831,526 | $6.1M | $7.4M | $19.9M |
| Invested capital | −$19.2M | −$20.4M | −$14.1M | −$23.1M | −$12.6M | −$5.1M | −$3.5M | −$79,269 | $5.7M | −$9.0M |
| Tangible asset value | $2.8M | −$6.0M | −$5.0M | $11.1M | $38.8M | −$1.2M | $440,826 | $6.7M | $2.9M | $13.1M |
| Net current asset value | −$2.6M | −$9.7M | −$8.8M | $10.3M | $38.2M | −$1.7M | −$558,030 | $6.1M | $7.4M | $12.2M |
| Graham number | — | — | — | $45.25 | — | — | — | — | — | — |
| Graham net-net per share | — | −$1.44 | −$2.08 | $0.46 | −$235.79 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $6.9M | $789.6M | — | $0 | $0 |
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 37.4% | 5,857.0% | 22.4% | 0.6% | 0.1% | — | — | — | — | 69.8% |
| Capex / operating cash flow | — | 10.6% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.18 | 13.54 | 16.41 | 2.61 | 0.55 | 0.41 | 1.58 | 4.85 | 0.00 | 2.05 |
| Stock-based compensation / revenue | 145.3% | 22,519.0% | 90.1% | 21.6% | 16.0% | — | — | — | — | 359.7% |
| R&D / revenue | 536,147.3% | 145,188.1% | 767.1% | 300.4% | 306.2% | — | — | — | — | 3,598.6% |
| SG&A / revenue | 850.7% | 85,405.4% | 402.8% | 118.4% | 83.5% | — | — | — | — | 1,351.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 142.3 | 21,995.4 | 172.4 | 52.0 | 29.3 | — | — | — | — | 770.5 |
| Days of inventory on hand | — | — | — | — | -7,895,968.6 | -6,482,270.7 | -24,747,378.3 | -117,495.6 | — | -1,475.5 |
| Days payables outstanding | 198.1 | 61.8 | 45.7 | 15,832.9 | 5,702.1 | 4,608.9 | 25,283.0 | 224.2 | — | 1,675.3 |
| Cash conversion cycle (days) | -55.9 | 21,933.6 | 126.7 | -15,780.9 | -7,901,641.3 | — | — | — | — | -2,380.4 |
| Receivables turnover | 2.57 | 0.02 | 2.12 | 7.02 | 12.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 |
| Payables turnover | 1.84 | 5.91 | 7.99 | 0.02 | 0.06 | 0.08 | 0.01 | 1.63 | 0.00 | 0.22 |
| Asset turnover | 0.04 | 0.00 | 0.09 | 0.20 | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Average receivables | $401,522 | $589,596 | $1.3M | $1.4M | $802,742 | $507,689 | $293,124 | $157,622 | $1.1M | $1.6M |
| Average payables | $1.3M | $2.4M | $2.7M | $2.1M | $1.6M | $1.1M | $771,444 | $383,962 | $877,110 | $1.8M |
| Average inventory | — | — | — | — | −$2.16B | −$1.48B | −$755.1M | −$201.2M | −$764,214 | −$1.6M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 72.8% | 0.0% |
Computed from DARE's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DARE valuation and financial ratios
It ended the year with $2.7 million of debt and $24.7 million in cash and short-term investments, a net cash position of $22.1 million.
See the DARE income statement, the DARE chart for price history, or the DARE stock overview for the latest quote and news.
DARE key metrics FAQ
How much debt does Daré Bioscience have?
Daré Bioscience had total debt of $2.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.93 and more cash than debt.
What is Daré Bioscience's current ratio?
Daré Bioscience's current ratio was 1.14 at the end of fiscal 2025: current assets were 1.14 times current liabilities.